Sanofi Consumer Healthcare India (SCHIL) shares experienced a powerful rally today, surging over 14% to reach an intraday high of ₹4,586 on the BSE. This bullish momentum follows the release of exceptional financial results for the fourth quarter and full year ending December 31, 2025. The company reported a 50% year-on-year increase in net profit for the December quarter, reaching ₹66.5 crore. Revenue for the same period saw a dramatic 47% jump to ₹251 crore. These figures mark a significant turnaround for the entity, which only recently emerged as a standalone listed company following its demerger from Sanofi India. A key driver of this growth was the successful relaunch of products that had previously faced voluntary recalls in the domestic market. Domestic sales grew by a healthy 23% in the final quarter, while export revenue surged more than 9 times over a low base from the previous year. For the full financial year 2025, the company’s performance was equally robust: - Total revenue rose 21% to ₹878.4 crore. - Net profit increased by 33% to ₹240 crore. - Basic Earnings Per Share (EPS) climbed to ₹104.27, up from ₹78.59. In a move to reward shareholders, the board has recommended a final dividend of ₹75 per equity share. When combined with previous interim payouts, the total dividend for the 2025 fiscal year reached ₹123 per share, highlighting the company’s strong cash position and commitment to investor returns. Management attributed the results to disciplined cost management, a better product mix, and sustained investment in core brands like Allegra, Avil, and Combiflam. The company also maintained an almost debt-free balance sheet and improved its operational efficiency, reducing its working capital cycle significantly. While the consumer healthcare arm soared, its former parent entity, Sanofi India, faced a different trajectory, with its share price slipping roughly 4.5% following a 32% decline in its own quarterly net profit. Market observers are now monitoring the impact of new Indian labor codes and changes in the global parent structure. Sanofi recently completed a 50% stake sale of its global consumer health business, Opella, to private equity firm CD&R, a move that may influence the strategic direction of the Indian subsidiary in the coming years.